Thermo Fisher Scientific (TMO) Accounts Payables (2009 - 2026)

Thermo Fisher Scientific has disclosed Accounts Payables across 18 years of filings, most recently posting $3.3 billion for Q1 2026.

• Quarterly Accounts Payables rose 9.68% year-over-year to $3.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 billion (up 9.68% YoY) and the FY2025 annual result came in at $3.6 billion, up 17.64% from the prior year.
• Accounts Payables fell to $3.3 billion in Q1 2026, from $3.6 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $3.6 billion in Q4 2025 and troughed at $2.4 billion in Q3 2023.
• A 5-year average of $2.9 billion and a median of $2.8 billion in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables gained 24.28% — and 2023, when it fell 15.05%.
• Tracing TMO's Accounts Payables over 5 years: stood at $3.4 billion in 2022, then declined by 15.05% to $2.9 billion in 2023, then increased by 7.21% to $3.1 billion in 2024, then increased by 17.64% to $3.6 billion in 2025, then decreased by 7.68% to $3.3 billion in 2026.
• Business Quant data shows TMO's Accounts Payables at $3.3 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.1 billion in Q3 2025.